Clovis' Rubraca, trailing PARP rivals, nabs England coverage thanks to NICE U-turn

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Oct 12, 2019 at 12:32 PM.

  1. #1 cafead, Oct 12, 2019 at 12:32 PM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,937
    Likes Received:
    3
    via Already behind in the PARP inhibitor race, Clovis Oncology’s Rubraca has at least won a reserved backing from England’s drug cost watchdog that helps level the playground in the U.K. region. Now, the late-comer will have to face two Big Pharma companies in their home country.

    article source
     
    Quote

Reply to Thread